Long-term valproate treatment is associated with polycystic ovaries and endocrine disorders in women with epilepsy. The mechanisms responsible for these effects are unknown, but both the epilepsy itself and the drug per se may be of importance. The aim of this study was to investigate possible effects of the drug on gonadal structure and function in animals with no epileptic disorders. Three groups, each of 15 female Wistar rats, were fed perorally with a valproate mixture (50 mg/kg or 200 mg/kg) or control solution once daily for 90 days, giving mean valproate concentrations within the normal human range. A significant, 20% increase in ovary weight was found in both low-(P = 0.027) and high-(P < 0.001) dose animals together with a significantly increased number of ovarian follicular cysts. Mean serum testosterone concentration was significantly reduced in both low-and high-dose animals. There was a non-significant trend towards reduced estrogen levels, while progesterone levels were unchanged. Even if the hormonal changes are somewhat different from those in humans, the findings demonstrate that changes in gonadal structure and endocrine function also occur in intact animals indicating a drug-specific effect. Our findings encourages further studies using animal models to elucidate possible mechanisms involved in the endocrine side-effects of antiepileptic drugs.
INTRODUCTION
Long-term valproate treatment is associated with polycystic ovaries and endocrine disorders in women with epilepsy [1] [2] [3] [4] . This is of major clinical importance with valproate being one of the most frequently used antiepileptic drugs worldwide. The mechanisms responsible for the endocrine side-effects are, however, still unknown. Some investigators have claimed that the effects are due to the epilepsy itself 5, 6 , while others have claimed a drug-specific effect on endocrine function 1, 2, 7 .
The aim of the present study was to investigate whether polycystic ovaries could also be induced by long-term valproate monotherapy in intact animals thereby indicating a drug-specific effect. This study also represents an attempt towards an animal model for studying possible mechanisms involved in the development of endocrine effects of antiepileptic drugs.
MATERIALS AND METHODS
Forty-five female Wistar rats were fed perorally through a gastric tube with a valproate or control mixture once daily for 90 days. All animals were at the age of 80 days at the beginning of the study. The drug used was a standard, commercially available valproate mix-ture, with a control mixture without the drug, kindly supplied by Desitin Pharma, Norway. The animals were divided in three groups, each of 15 animals, receiving either valproate 50 mg/kg, 200 mg/kg or a control solution. The animals were weighed at the first study day and the doses were later adjusted for weight gain every week.
After 90 days, the animals were sacrificed 4 hours after their last dose of valproate. When sacrificed, all animals were in late diestrus/early proestrus according to vaginal smears. The blood was collected and serum frozen at −20 • C until analysis. The ovaries were weighed and thereafter immediately fixed in formalin. For microscopical evaluation of the ovaries, three mid-ovarian sections were cut and the total number of cysts, follicles and corpora lutea were counted. The mid-ovarian section with the highest number of cysts, follicles or corpora lutea from each animal was used for the statistical analysis.
Serum testosterone and progesterone concentrations were measured by the Chiron Diagnostics ACS:180 automated chemiluminescence system using an ACS:180 analyser. Serum 17-beta-estradiol concentrations were analyzed by radioimmunoassay with kits obtained from Orion Diagnostica (Turku, Finland) after extraction of the serum samples with ether/ethyl acetate (9:1). The concentrations of serum-free testosterone were measured by radioimmunoassay using kits obtained from Diagnostic Products Corp. (Los Angeles, CA). Serum valproate concentrations were analyzed by a fluorescence polarization immunoassay system using an AxSym analyzer (Abbott Diagnostic Division, Irving, Tx).
The statistical analyses were performed with a oneway ANOVA technique using a commercially available software package (SPSS). All significant observations were checked and confirmed with a nonparametric Kruskall-Wallis test.
RESULTS
All animals tolerated the treatment and the gastric tube feeding without any signs of discomfort or reduced motor activity. Two animals, one from the control and one from the low-dose group, died because of esophageal rupture by the gastric tube with concommittant intrathoracic bleeding, according to autopsy findings. Mean valproate concentration when sacrificed 4 hours after last dose was 72 µmol/l (n = 14) in low-dose and 200 µmol/l (n = 15) in high-dose animals. In the high-dose group, additional serum concentration measurements showed that the mean serum level of valproate was 999 µmol/l (n = 3) 2 hours, 157 µmol/l (n = 1) 6 hours, and 3 µmol/l (n = 2) 24 hours after the last dose.
A significant, about 20% higher ovary weight was found in both low-and high-dose animals when compared with the controls (Table 1) . Mean total body weight was unchanged with 251 g in controls and 258 g and 248 g in low-and high-dose groups, respectively. The mean number of cysts per section increased progressively and significantly with higher valproate doses from 0.5 cysts/section in the control animals to 0.86 and 1.27 in the low-and high-dose groups, respectively (Table 1) (Fig. 1) .
A significant reduction in serum testosterone concentration was observed with an approximately 40% reduction in high-dose animals as compared with the control animals ( Table 1) . A progressive, dosedependent reduction in free testosterone concentration was also observed. Serum estradiol concentration was markedly reduced by about 35% after high-dose valproate treatment. The free testosterone and estrogen data did, however, not reach statistical significance. This might be due to the low number of animals and the large between-animal variability. Progesterone was unchanged after valproate treatment. In addition, no changes were observed in albumin concentrations. 
DISCUSSION
This is the first report to have been able to demonstrate morphological changes in the ovaries and changes in sex steroid hormones in animals after long-term valproate treatment. An increase in ovary weight and the increased number of cystic formations in the ovaries of intact, non-epileptic animals are in general agreement with observations in humans of polycystic ovaries and endocrine changes in women on valproate monotherapy [1] [2] [3] . This implies that valproate treatment per se leads to endocrine changes and alterations of ovarian morphology independent of the species studied and underlying epilepsy.
The endocrine changes in the animals seem, however, to differ from those previously observed in humans 2 with a decrease rather than increase in testosterone. However, new observations in humans have shown that polycystic ovaries are not always associated with hyperandrogenism in female patients 8 . Earlier animal studies have also demonstrated testicular atrophy in male rats and dogs, indicating reduced androgen levels in agreement with our findings 9, 10 .
The valproate doses used in our study might seem high when compared to human doses. However, our maximum dose of 200 mg/kg/day was within the human therapeutic range on a mg/m 2 basis. In accordance with this, in our study the serum concentrations measured 4 hours after the last dose were even below the lower therapeutic range in humans. It might be speculated that a high peak concentration of valproate after a single dose could be responsible for the effects of the drug on the endocrine system. However, the drug was given perorally requiring normal absorption time from the bowel. Also, the effects on the ovaries in humans are observed after conventional peroral treatment. It is thus unlikely that abrupt fluctuations in valproate concentrations in the rats are of any major importance for the observed changes in ovarian morphology and endocrine functions.
It is further unlikely that the effects observed are due to other toxic effects of the drug in the animals. There was no difference in weight gain or observed motor activity between the different groups of animals indicating normal thriving in the animals. One-and three-month studies with valproate in Long-Evans rats found a 'no-toxic-effect' dose of 270 mg/kg/day 11 . In a six-month feeding study in Sprague-Dawley rats, no toxicity was observed at dosages of valproate of 341 mg/kg/day in males and 416 mg/kg/day in females 11 . A light microscope examination of the liver, heart, kidney, lung and brain of all our animals did not show any abnormalities 12 . Thus, most likely, valproate exerts a specific effect on ovarian morphology.
In conclusion, our study has shown that valproate also induces endocrine changes and alterations in ovarian morphology in an animal model. Although the changes in hormone levels do not seem to be directly applicable to humans, the results encourage further attempts to study endocrine side-effects of antiepileptic drugs.
